Stromal and tumor immune microenvironment reprogramming through multifunctional cisplatin-based liposomes boosts the efficacy of anti-PD-1 immunotherapy in pancreatic cancer

Yu, Hang; Zhu, Wenting; Lin, Caiyan; Jia, Menglei; Tan, Xiaoxiao; Yuan, Zhongwen; Feng, Senglin; Yan, Pengke

doi:10.1039/d3bm01118f

Biomater. Sci.

2024

DOI: 10.1039/d3bm01118f

|View full text |Cite

Stromal and tumor immune microenvironment reprogramming through multifunctional cisplatin-based liposomes boosts the efficacy of anti-PD-1 immunotherapy in pancreatic cancer

Hang Yu,

Wenting Zhu,

Caiyan Lin

et al.

Abstract: Application of ATF decorated cisplatin liposomes and anti PD-1 antibodies to mice with pancreatic cancer showed improved efficacy by enhancing drug penetration and remodeling the immunosuppressive microenvironment.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Preprint1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 59 publications

(73 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Identification of novel tumor antigens and immune subtypes in breast cancer patients for mRNA vaccine development

Yu,

Liu,

et al. 2024

Preprint

View full text Add to dashboard Cite

Background:Breast cancer has overtaken lung cancer as the world's most common malignancy. Despite the development of some mRNA vaccines, no satisfactory vaccination for breast cancer has entered clinical application. Methods:In this study, we used multiple analyses of expression datasets from public sources to find new possible tumor antigens for breast cancer and to hunt for potential treatment-sensitive patients. Results: We identified the antigens DST, ANO6, LAMA3, and NEDD9 as putative candidates. Furthermore, we found five predictive genes to identify specific patients inclined for vaccination, namely TRBC2, CD3D, CD27, CD3E, and TRBV28. Following that, we discovered three immunological subtypes of breast cancer, Cluster 1 and Cluster 3, which were recognized as "cold tumors" with minimal immune activity and were more likely to respond to vaccination. We uncovered that Cluster 1 and Cluster 3 could be further separated into two subgroups, each with distinct immune cell infiltration patterns, suggesting that vaccine responses could differ among these patients. The findings of our study lay theoretical foundation for the development of mRNA vaccine and provide new opportunities for personalized treatment.

show abstract

Identification of novel tumor antigens and immune subtypes in breast cancer patients for mRNA vaccine development

Yu,

Liu,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Stromal and tumor immune microenvironment reprogramming through multifunctional cisplatin-based liposomes boosts the efficacy of anti-PD-1 immunotherapy in pancreatic cancer

Abstract: Application of ATF decorated cisplatin liposomes and anti PD-1 antibodies to mice with pancreatic cancer showed improved efficacy by enhancing drug penetration and remodeling the immunosuppressive microenvironment.

Cited by 1 publication

References 59 publications

Identification of novel tumor antigens and immune subtypes in breast cancer patients for mRNA vaccine development

Identification of novel tumor antigens and immune subtypes in breast cancer patients for mRNA vaccine development

Contact Info

Product

Resources

About